Objective: The aim of this study was to systematically assess the effect and safety of salvianolate on chronic renal failure(CRF). Method: The reports about randomized controlled trials of Salvianolate were comprehensively search

and the quality was evaluated. Then the Meta analysis of those reports meeting the criteria was carried out. Result: In this study

8 randomized controlled trials were included for the systematic review. A Meta-analysis showed that the combination of salvianolate and conventional treatment had better efficacy on both overall clinical manifestations and GRF than the conventional monotherapy. The odds ratio (OR) and 95% confidence interval (95%CI) from the comparison of the improvement on overall clinical manifestations were 3.22 and (1.61

6.38) respectively. The level of GRF was [WMD=11.36

95%CI(6.64

16.08)]

the level of SCR and BUN were as following:[WMD=38.35

95%CI(1.47

75.24)] and [WMD=1.84

95%CI(0.97

2.70)] respectively

and the microalbuminuria level was [WMD=6.52

95%CI(-1.86

14.90)]

the β2-microglobulin level was [WMD=1.41

95%CI(1.04

1.79)]

and the levels of cystatin C

UCR and HGB were as the following:[WMD=0.56

95%CI(0.11

1.01)]

[WMD=0.56

95%CI(0.11

1.01)] and [WMD=12.60

95%CI(7.44

17.77)]

respectively. Conclusion: The combination of salvianolate and conventional treatment may have better effectiveness and safety for CRF than the regular conventional treatment

however

well designed randomized controlled multicenter clinical trial are needed for further confirmation.